NDA and license for the procaterol metered-dose inhaler have been returned to Otsuka "for business reasons," Warner-Lambert said. The company noted it has moved away from developing respiratory therapies. The NDA, which has been at FDA since 1985, was to have been discussed at the next meeting of FDA's Pulmonary-Allergy Drugs Advisory Committee on Feb. 25-26, but was subsequently dropped from the committee's agenda ("The Pink Sheet" Feb. 15, In Brief).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth